SCHEMBL24108948

SCHEMBL24108948

Cc1ccccc1-c1nc(O)nc2ccc(Br)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 2/20 0.49
▸ PTGFR P43088 1/20 0.47
▸ KMT2A Q03164 3/20 0.46
▸ GAA P10253 1/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ MAPT P10636 3/20 0.45
▸ PRNP P04156 2/20 0.45
▸ PPARG P37231 1/20 0.42
▸ NR2E3 Q9Y5X4 1/20 0.42
▸ NCOR2 Q9Y618 1/20 0.42
▸ CSNK2A2 P19784 1/20 0.42
▸ CSNK2B P67870 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ CASP3 P42574 1/20 0.41
▸ THRB P10828 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.41
▸ ATM Q13315 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ PTGES O14684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24109001 0.82 RXFP1 (0.44) RXFP1PTGFRKMT2AGAAMAPT
SCHEMBL24108900 0.80 PRNP (0.61) RXFP1KMT2AMAPTPRNPPPARG
SCHEMBL24108914 0.79 ADORA2A (0.42) PTGFRADORA2AMAPTCSNK2A2CSNK2B
SCHEMBL18075771 0.77 PTGFR (0.64) RXFP1PTGFRKMT2APRNPPPARG
SCHEMBL24109077 0.77 RXFP1 (0.46) RXFP1KMT2AGAAMAPTPRNP
SCHEMBL12575801 0.75 MPO (0.58) RXFP1KMT2AGAAMAPTPRNP
SCHEMBL18075773 0.74 PTGFR (0.53) RXFP1PTGFRPRNPPPARGNR2E3
SCHEMBL24108957 0.74 DHODH (0.42) RXFP1PTGFRKMT2AGAAMAPT
SCHEMBL3498669 0.71 HTT (0.44) RXFP1KMT2AGAAMAPTPRNP
SCHEMBL26858063 0.71 CTSD (0.49) KMT2AALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. 2023-08-17 — — US disclosed
WO-2021252680-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS IDEAYA BIOSCIENCES, INC. (US) 2021-12-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257359-A1 4-ARYLQUINAZOLINE DERIVATIVES AS METHIONINE ADENOSYLTRANSFERASE 2A INHIBITORS MAT2A, MAT2B, MAT1A RXFP1 4779/4885PTGFR 2764/4885KMT2A 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback